Welcome to LookChem.com Sign In|Join Free
  • or
7,8-Didehydro-4,5α-epoxy-3-ethoxy-17-methylmorphinan-6β-ol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

47252-01-7

47252-01-7 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.

47252-01-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 47252-01-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,7,2,5 and 2 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 47252-01:
(7*4)+(6*7)+(5*2)+(4*5)+(3*2)+(2*0)+(1*1)=107
107 % 10 = 7
So 47252-01-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14+,18-,19-/m0/s1

47252-01-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-ethoxy-4,5α-epoxy-17-methyl-morphin-7-en-6β-ol

1.2 Other means of identification

Product number -
Other names 3-Aethoxy-4,5α-epoxy-17-methyl-morphin-7-en-6β-ol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:47252-01-7 SDS

47252-01-7Relevant academic research and scientific papers

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

-

, (2008/06/13)

Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.